Aug. 6, 2012
/PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa / KVb) ("K-V" or "the Company") today announced that its Class A and Class B common shares may be traded in the over the counter (OTC) market following the Company's suspension from the New York Stock Exchange ("NYSE"). However, K-V cannot ensure that either class of stock will be, or will continue to be, traded. Trading in the OTC market may result in significantly lower trading volumes and liquidity for investors seeking to buy or sell shares of K-V's common stock.
Earlier today, the Company received notice from the NYSE that trading in its Class A and Class B common shares would be suspended, pending delisting, following the Company's voluntary filing for protection under Chapter 11 of the U.S. Bankruptcy Code on
, 2012. The Company will not be challenging the NYSE's delisting action.
Court documents, claims forms and other documents related to K-V's Chapter 11 can be found at
. Additional information and frequently asked questions (FAQs) for shareholders can be found at
About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.
For further information about K-V Pharmaceutical Company, please visit the Company's corporate website at
Cautionary Note Regarding Forward-looking Statements
This release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and which may be based on or include assumptions concerning our operations, future results and prospects. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.